Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib vs Azacitidine in HMA-Naive IDH1-Mutated MDS
NCT06465953Phase 3Recruiting
- Sponsor
- Servier
- Start
- Dec 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of ivosidenib in myelodysplastic syndrome (MDS), sponsored by Servier. Started Dec 2024; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06465953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465953.